Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 2/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514187 | 0.85 | PTGDR2 (0.40) | PTGDR2SRCSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13981380 | 0.85 | SRC (0.43) | PTGDR2SRCSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2986624 | 0.85 | PTGDR2 (0.40) | PTGDR2SRCSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL20783011 | 0.85 | PTGDR2 (0.46) | PTGDR2SRCALDH1A1CYP2C19RECQL | |
| SCHEMBL23910877 | 0.83 | PTGDR2 (0.39) | ENPP3ENPP1PTGDR2SRCSMN1; SMN2 | |
| SCHEMBL23910875 | 0.83 | PTGDR2 (0.39) | ENPP3ENPP1PTGDR2SRCSMN1; SMN2 | |
| SCHEMBL29959159 | 0.83 | PTGDR2 (0.48) | ENPP3ENPP1PTGDR2SRCSMN1; SMN2 | |
| SCHEMBL1154907 | 0.83 | PTGDR2 (0.48) | ENPP3ENPP1PTGDR2SRCSMN1; SMN2 | |
| SCHEMBL26503032 | 0.82 | PTGDR2 (0.44) | PTGDR2SRCCYP2C19RECQLSLC40A1 | |
| SCHEMBL15586649 | 0.82 | ENPP3 (0.39) | ENPP3ENPP1PTGDR2SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | disclosed |
| CN-116589461-A | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116589462-A | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-111247144-B | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11498919-B2 | Azaindolylpyridone and diazaindolylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2022-11-15 | — | — | US | disclosed |
| EP-4001278-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001278-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3672967-B1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3672967-B1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-04-29 | — | — | US | disclosed |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-04-29 | — | — | US | disclosed |
| EP-3672967-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-111247144-A | Azaindolylpyridinone compounds and diazaindolylpyridinone compounds | 思普瑞特生物科学公司 | 2020-06-05 | — | — | CN | disclosed |
| WO-2019038384-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | ENPP3 338/4885ENPP1 342/4885PTGDR2 498/4885 |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | ENPP3 338/4885ENPP1 342/4885PTGDR2 498/4885 |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | ENPP3 1611/4885ENPP1 1543/4885PTGDR2 4346/4885 |
| US-11498919-B2 | Azaindolylpyridone and diazaindolylpyridone compounds | AZI2, IAPP, ZFX | ENPP3 338/4885ENPP1 342/4885PTGDR2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.